Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens
- PMID: 39452768
- PMCID: PMC11510143
- DOI: 10.3390/pathogens13100896
Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens
Abstract
The continued rise in antimicrobial resistance poses a serious threat to public health worldwide. The use of phages that can have bactericidal activity without disrupting the normal flora represents a promising alternative treatment method. This practice has been successfully applied for decades, mainly in Eastern Europe, and has recently been used as an emergency therapy for compassionate care in the United States. Here, we provide a comprehensive review of the pre-clinical and clinical applications of phage therapy concerning three major Gram-negative pathogens: Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The advantages and the challenges of expanding the usage of phages as an alternative or adjunctive treatment for antimicrobial-resistant bacterial infections are discussed. We emphasize the virologic complexities of using the highly adaptable phage populations as molecular tools, along with antibiotic chemical compounds, to effectively combat rapidly coevolving pathogenic bacteria in the host microenvironment. Pre-clinical studies, isolated clinical reports and a few randomized clinical trials have shown that bacteriophages can be effective in treating multidrug-resistant bacterial infections. The ability of some phages to revert the resistance against antibiotics, and possibly also against the human complement and other phages, appears to be a great advantage of phage therapy despite the inevitable emergence of phage-resistant strains. Bacteriophages (or specific phage-derived products) can enhance antimicrobial efficacy by reducing bacterial virulence via the alteration of basic bacterial structures, primarily of the cellular wall and membrane. Although several issues remain open regarding their effective clinical application, it appears that phage-based therapeutics in combination with antibiotics can provide an effective solution to the spread of antimicrobial resistance.
Keywords: Acinetobacter baumannii; Klebsiella pneumoniae; Pseudomonas aeruginosa; antimicrobial resistance (AMR); bacteriophages; phage therapy; phagotherapy.
Conflict of interest statement
The authors declare no conflicts of interest.
References
-
- National Burreau of Economic Research. [(accessed on 21 August 2024)]. Available online: https://www.nber.org/bh-20192/reductions-mortality-rates-and-health-disp....
-
- National Academies of Sciences, Engineering, and Medicine. Health and Medicine Division. Board on Population Health and Public Health Practice. Committee on the Long-Term Health and Economic Effects of Antimicrobial Resistance in the United States. The Health and Economic Burden of Resistance . In: Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Palmer G.H., Buckley G.J., editors. National Academies Press; Washington, DC, USA: 2021. [(accessed on 21 August 2024)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK577288/ - PubMed
-
- Centers for Disease Control and Prevention . Antibiotic Resistance Threats in the United States. Centers for Disease Control and Prevention; Atlanta, GA, USA: 2019.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical